

26 November 2025

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

RESULTS OF ANNUAL GENERAL MEETING

In accordance with Listing Rule 3.13.2 and Section 251AA of the *Corporations Act 2001* (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

Yours sincerely,
NEURIZON THERAPEUTICS LIMITED



Stefan Ross
Company Secretary

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited

For personal use only

**Neurizon Therapeutics Limited
Annual General Meeting
Wednesday, 26 November 2025
Voting Results**

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001 (Cth)* and *ASX Listing Rule 3.13.2*:

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	If s250U applies	S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried /Not Carried
1.	Adoption of Remuneration Report	Ordinary	N/A	P	81,889,212 88.89%	9,810,152 10.65%	423,545 0.46%	109,935 -	113,569,170 89.69%	13,060,152 10.31%	917,940 -	Carried
2.	Re-election of Marcus Hughes as a Director of the Company	Ordinary	N/A	P	102,460,856 96.63%	3,139,075 2.96%	438,809 0.41%	5,047,973 -	138,214,083 97.78%	3,139,075 2.22%	5,047,973 -	Carried
3.	Ratification of prior issue of Shares	Ordinary	N/A	P	99,006,944 96.19%	3,485,603 3.39%	438,809 0.43%	5,047,973 -	128,563,679 97.36%	3,485,603 2.64%	5,047,973 -	Carried
4.	Approval to issue shares to Mr Sergio Duchini (or his nominee(s)) in relation to the Placement	Ordinary	N/A	P	102,349,405 97.76%	1,938,961 1.85%	407,482 0.39%	6,390,865 -	138,071,305 98.62%	1,938,961 1.38%	6,390,865 -	Carried
5.	Approval to issue shares to Mr Marcus Hughes (or his nominee(s)) in relation to the Placement	Ordinary	N/A	P	87,209,825 95.25%	3,940,461 4.30%	407,482 0.45%	5,075,076 -	122,931,725 96.89%	3,940,461 3.11%	5,075,076 -	Carried

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	If s250U applies		S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*
6.	Approval to issue shares to Dr Michael Thurn (or his nominee(s)) in relation to the Placement	Ordinary	N/A	P	100,858,896 97.74%	1,824,206 1.77%	507,482 0.49%	5,075,076 -	136,680,796 98.68%	1,824,206 1.32%	5,075,076 -	Carried
7.	Approval to issue shares to Dr Katie MacFarlane (or her nominee(s)) in relation to the Placement	Ordinary	N/A	P	103,431,337 97.81%	1,909,660 1.81%	407,482 0.39%	5,075,076 -	139,153,237 98.65%	1,909,660 1.35%	5,075,076 -	Carried
8.	Amendments to the Company's Constitution	Special	N/A	P	106,124,535 96.91%	2,855,703 2.61%	523,939 0.48%	1,582,536 -	141,962,892 98.03%	2,855,703 1.97%	1,582,536 -	Carried
9.	Approval of 10% Placement Facility	Special	N/A	P	65,010,832 58.56%	45,467,765 40.96%	534,203 0.48%	73,913 -	99,859,453 68.24%	46,467,765 31.76%	73,913 -	Not Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.